Journal article
Evaluation of New Anti-Infective Drugs for the Treatment of Infective Endocarditis
Clinical infectious diseases, v 15(Supplement-1), pp S89-S95
Nov 1992
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
These guidelines describe the design and implementation of clinical trials to assess the safety and efficacy of anti-infective drugs for the treatment of infective endocarditis. Identification and enrollment of patients in clinical trials is based on a modification of traditional criteria. To accrue a sufficient number of patients, only those with streptococcal or staphylococcal endocarditis should be included in studies. Results of treatment with approved drugs allow for projection of expected bacteriologic cure rates and survival rates. Prospective randomized, double-blind studies are recommended. These guidelines are based on the premise that future protocols may include shorter courses of therapy, combinations of drugs, or progression from parenteral to oral therapy. Clinical response is judged as cure, failure, or indeterminate; there is no “improved” category. Microbiologic response is categorized as eradication, persistence, or relapse. When a patient has shown no clinical evidence of active disease for a protracted period, there may be no need to perform a posttreatment blood culture; for such patients, the microbiologie response is termed presumptive eradication. Several months of follow-up may be necessary to detect late relapses.
Metrics
Details
- Title
- Evaluation of New Anti-Infective Drugs for the Treatment of Infective Endocarditis
- Creators
- Walter R. Wilson - Mayo ClinicDavid N. Gilbert - Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Portland, Oregon, Miami, Florida, West Los Angeles, California, Baltimore, Maryland, Philadelphia, PennsylvaniaAlan L. Bisno - Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Portland, Oregon, Miami, Florida, West Los Angeles, California, Baltimore, Maryland, Philadelphia, PennsylvaniaLawrence R. Freedman - Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Portland, Oregon, Miami, Florida, West Los Angeles, California, Baltimore, Maryland, Philadelphia, PennsylvaniaCraig Smith - Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Portland, Oregon, Miami, Florida, West Los Angeles, California, Baltimore, Maryland, Philadelphia, PennsylvaniaGeorge Drusano - Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Portland, Oregon, Miami, Florida, West Los Angeles, California, Baltimore, Maryland, Philadelphia, PennsylvaniaDonald Kaye - WinnMed
- Publication Details
- Clinical infectious diseases, v 15(Supplement-1), pp S89-S95
- Publisher
- The University of Chicago Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:A1992JX58600009
- Scopus ID
- 2-s2.0-84963001762
- Other Identifier
- 991019184190204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Microbiology